Novo Nordisk A/S (NVO)
What changed in recent filings
- Institutions — 3 new · 1 added · 2 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Novo Nordisk A/S
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 1 → 2026 Q2: 7 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Novo Nordisk A/S
Institutions we track that reported holding this stock in their most recent 13F.
- Baillie Gifford & Counder 0.01% of portfolio · since 2024 Q1
- Tudor Investment Corp0.01% of portfolio · since 2025 Q4
- Maverick Capital0.70% of portfolio · since 2026 Q1
- Dodge & Cox0.51% of portfolio · since 2026 Q1
- Point72 Asset ManagementNew this quarterunder 0.01% of portfolio · since 2026 Q2
- Caisse de depot (Quebec)0.04% of portfolio · held as of 2026 Q2 or earlier
- Capital World Investors0.03% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Novo Nordisk A/S is classified under the Biotech & Health sector. See peers below.
Novo Nordisk A/S key financials
Based on SEC filings · as of Dec 31, 2025 · IFRS
Tap a metric name to see its meaning in the glossary.
Novo Nordisk A/S vs Biotech & Health sector benchmark
Median of 35 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
ETFs holding Novo Nordisk A/S
Per SEC N-PORT · 2026-06-30 · by weight · factual
NVO on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
NVO FAQ
What is Novo Nordisk A/S (NVO)?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Novo Nordisk A/S's key financials?
As of Dec 31, 2025 in SEC filings: Revenue growth (YoY) 6.4%, Net margin 33.1%, ROE 52.8%, Debt-to-equity 0.69x. Definitions and interpretation are available on Stocklore.
Where can I analyze Novo Nordisk A/S (NVO) stock?
On Stocklore you can see NVO's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.